GlassScriptPhysician profile
Layne T Barker
NPI 1992781918
$12,667.03
in general payments reported to CMS, 2019-2025
67 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,343 · 2021: $1,742 · 2022: $4,991 · 2023: $1,343 · 2024: $1,300 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.33 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,949.97 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Lilly USA, LLC | $788.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $650.16 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $542.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Novo Nordisk INC | $472.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $465.51 | 2019-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.31 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $442.19 | 2020-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $440.17 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $333.66 | 2019-2025 | |
| Abbott Laboratories | $312.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $255.80 | 2021 | |
| Amarin Pharma, INC. | $219.28 | 2020-2021 | |
| Axsome Therapeutics, INC. | $152.02 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $120.34 | 2019-2023 | Trintellix |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.